Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBT Margin (2020 - 2025)

Historic EBT Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 29.5%.

  • Tango Therapeutics' EBT Margin rose 2803200.0% to 29.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 150.99%, marking a year-over-year increase of 1329600.0%. This contributed to the annual value of 309.24% for FY2024, which is 310600.0% down from last year.
  • Tango Therapeutics' EBT Margin amounted to 29.5% in Q3 2025, which was up 2803200.0% from 1220.31% recorded in Q2 2025.
  • Tango Therapeutics' 5-year EBT Margin high stood at 29.5% for Q3 2025, and its period low was 1220.31% during Q2 2025.
  • In the last 5 years, Tango Therapeutics' EBT Margin had a median value of 419.8% in 2022 and averaged 412.22%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 2892600bps in 2023, then plummeted by -10920800bps in 2025.
  • Tango Therapeutics' EBT Margin (Quarter) stood at 382.59% in 2021, then decreased by -18bps to 452.49% in 2022, then decreased by -25bps to 565.57% in 2023, then plummeted by -62bps to 913.8% in 2024, then soared by 103bps to 29.5% in 2025.
  • Its EBT Margin stands at 29.5% for Q3 2025, versus 1220.31% for Q2 2025 and 738.91% for Q1 2025.